INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $37.22 million. The enterprise value is $13.90 million.

Market Cap	37.22M
Enterprise Value	13.90M

Important Dates

The next estimated earnings date is Thursday, May 7, 2026, after market close.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 26.59 million shares outstanding. The number of shares has increased by 24.13% in one year.

Current Share Class	26.59M
Shares Outstanding	26.59M
Shares Change (YoY)	+24.13%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	11.17%
Owned by Institutions (%)	19.30%
Float	22.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	752.36
Forward PS	n/a
PB Ratio	1.60
P/TBV Ratio	1.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	278.02
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.55, with a Debt / Equity ratio of 0.04.

Current Ratio	3.55
Quick Ratio	3.48
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -165.16% and return on invested capital (ROIC) is -67.65%.

Return on Equity (ROE)	-165.16%
Return on Assets (ROA)	-53.66%
Return on Invested Capital (ROIC)	-67.65%
Return on Capital Employed (ROCE)	-128.97%
Weighted Average Cost of Capital (WACC)	8.89%
Revenue Per Employee	$2,381
Profits Per Employee	-$2.19M
Employee Count	21
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.10% in the last 52 weeks. The beta is 0.89, so INmune Bio's price volatility has been lower than the market average.

Beta (5Y)	0.89
52-Week Price Change	-82.10%
50-Day Moving Average	1.30
200-Day Moving Average	1.77
Relative Strength Index (RSI)	55.57
Average Volume (20 Days)	286,435

Short Selling Information

The latest short interest is 3.37 million, so 12.67% of the outstanding shares have been sold short.

Short Interest	3.37M
Short Previous Month	3.43M
Short % of Shares Out	12.67%
Short % of Float	15.20%
Short Ratio (days to cover)	7.85

Income Statement

In the last 12 months, INmune Bio had revenue of $50,000 and -$45.93 million in losses. Loss per share was -$1.86.

Revenue	50,000
Gross Profit	50,000
Operating Income	-30.87M
Pretax Income	-45.93M
Net Income	-45.93M
EBITDA	-30.79M
EBIT	-30.87M
Loss Per Share	-$1.86

Full Income Statement

Balance Sheet

The company has $24.75 million in cash and $1.03 million in debt, giving a net cash position of $23.72 million or $0.89 per share.

Cash & Cash Equivalents	24.75M
Total Debt	1.03M
Net Cash	23.72M
Net Cash Per Share	$0.89
Equity (Book Value)	23.52M
Book Value Per Share	0.88
Working Capital	21.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$22.58 million and capital expenditures -$1.04 million, giving a free cash flow of -$23.62 million.

Operating Cash Flow	-22.58M
Capital Expenditures	-1.04M
Depreciation & Amortization	84,000
Net Borrowing	n/a
Free Cash Flow	-23.62M
FCF Per Share	-$0.89

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-61,738.00%
Pretax Margin	-91,866.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.13%
Shareholder Yield	-24.13%
Earnings Yield	-122.10%
FCF Yield	-62.80%

Analyst Forecast

The average price target for INmune Bio is $5.40, which is 285.71% higher than the current price. The consensus rating is "Buy".

Price Target	$5.40
Price Target Difference	285.71%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	208.21%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of -3.76 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.76
Piotroski F-Score	2